Surprise government inspections are coming in China’s medical device sector.
Beginning in September, inspectors from the China Food and Drug Administration (CFDA) are going to start making unannounced visits to medical device manufacturers with products registered to be sold in China.
According to Stewart Eisenhart of the Emergo Group, the surprise inspections are authorized by a 2012 “Working Procedures for Unannounced Inspection of Medical Device Manufacturers” regulation established by the CFDA’s predecessor, the Sate Food and Drug Administration.
Inspection Measures
The CFDA issued the “Measures” for the unannounced inspections in July 7, 2015. According to the CFDA, the Measures comprise, “35 articles in five chapters, including the general provisions, initiating, inspection, handling and supplementary provisions.”
According to the CFDA order, the inspections will be warranted in cases such as:
- Complaints of a device’s quality or safety occur
- Improper or inadequate adverse event reporting
- Serious violations of quality system compliance
- Other quality or safety risks involving a device are suspected
If the investigators find potential problems, the CFDA may take disciplinary actions such as warning letters, additional investigations, product recalls or revocation of quality system certification.
Penalties
In addition, Eisenhart previously cited the law firm CMS Cameron McKenna, which said if officials find any violations during such inspections, they may turn inspections over to local CFDA investigators, “which in turn could result in possible sanctions. However, a manufacturer may appeal, explain or immediately correct a found violation in order to reduce the likelihood of further investigation and penalties.”
The new regulations from the previous regulatory body also suggested that lighter penalties may be handed out, “if the violator makes the initial effort to correct improper actions and mitigate public health risks caused by its product, or in cases where the violator has been coerced by another entity to commit an offense, ” wrote Eisenhart.
A similar inspection regimen already exists for pharmaceuticals.
